ArQule Presents Results From Phase 1b Expansion Study of ARQ 092 at the 2015 European Cancer Conference

By: via Benzinga
ArQule, Inc. (NASDAQ: ARQL) today announced preliminary results for the ongoing phase 1b expansion study in oncology for ARQ 092, an ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.